Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three‐factor model | Request PDF
Cancers | Free Full-Text | The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | Annals of Hematology
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Imbruvica Capsules and Tablets - NPS MedicineWise
Frontiers | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia | Nature Communications
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Updates in the Management of CLL/SLL: Sequencing Therapy and the Role of Minimal Residual Disease Testing in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Full article: Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3
CHRONIC LYMPHOCYTIC LEUKEMIA
Imbruvica Capsules and Tablets - NPS MedicineWise
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
PDF) Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
